ArticleEJNMMI radiopharmacy and chemistry2021
A suitable time point for quantifying the radiochemical purity of
Article in EJNMMI radiopharmacy and chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Inline gamma spectroscopy and liquid scintillation HPLC reveal daughters inEJNMMI radiopharmacy and chemistry · 2026Article
- Review
- Quality control of actinium-225 andEJNMMI radiopharmacy and chemistry · 2026Article
- [EJNMMI radiopharmacy and chemistry · 2025Article
- Towards DFO*Pharmaceutics · 2025Article
- Comparison of ZnS(Ag) Scintillator and Proportional Counter Tube for Alpha Detection in Thin-Layer Chromatography.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Targeted Alpha Therapy: All We Need to Know aboutPharmaceuticals (Basel, Switzerland) · 2023Review
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board.EJNMMI radiopharmacy and chemistry · 2023Review
- Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review.Pharmaceutics · 2023Review
- Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy.Pharmaceutics · 2023Article
- Review
- Study ofMaterials (Basel, Switzerland) · 2022Article
- Gamma counting protocols for the accurate quantification ofEJNMMI radiopharmacy and chemistry · 2022Article
- The determination of the radiochemical purity of Actinium-225 radiopharmaceuticals: a conundrum.EJNMMI radiopharmacy and chemistry · 2022Article
- Ac-EAZY! Towards GMP-Compliant Module Syntheses ofPharmaceuticals (Basel, Switzerland) · 2021Article
- A third generation PSMA-targeted agent [Nuclear medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs
resultsSix ligands were conjugated to macrocyclic metal chelators and labeled with actinium-225 under conditions designed to generate diverse incorporation yields. RCP was determined by radio thin layer chromatography (radioTLC) followed by exposure of the TLC plate on a phosphor screen either 0.5, 2, 3.5, 5, 6.5, or 26 h after the plate was developed. The dataset was used to create models for predicting the true RCP for any pre-equilibrium measurement taken at an early time point. The 585 TLC measurements span RCP values of 1.8-99.5%. The statistical model created from these data predicted an independent data set with high accuracy. Predictions made at 0.5 h are more uncertain than predictions made at later time points. This is primarily due to the decay of bismuth-213. A measurement of RCP > 90% at 2 h predicts a true RCP > 97% and guarantees that RCP will exceed 90% after secular equilibrium is reached. These findings were independently validated using NaI(Tl) scintillation counting and high resolution gamma spectroscopy on a smaller set of samples with 10% ≤ RCP ≤ 100%.
conclusionsRCP of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.